Regulatory 2024-08-15 | Half-Year Report 2024: Orviglance Completes Clinical Development with Successful Phase 3 Study PDF Report Presentation Webcast
Regulatory 2024-05-16 | Quarterly Report Q1: Primary Endpoint Met with Strong Headline Results in Orviglance Phase 3 Study PDF Report Presentation Webcast
Regulatory 2024-02-09 | Q4 and Full Year Report 2023: Strengthened Financial Position Ahead of SPARKLE Phase 3 Study Headline Results in May PDF Report Presentation Webcast
Regulatory 2023-11-08 | QUARTERLY REPORT Q3 2023: Re-evaluation of SPARKLE Phase 3 Study Images Progresses According to Plan PDF Report Presentation Webcast
Regulatory 2023-08-18 | Half-Year report 2023: Re-evaluation required after intra-reader inconsistency in scoring of images from phase 3 study SPARKLE PDF Report Presentation Webcast
Regulatory 2023-05-11 | QUARTERLY REPORT Q1 2023: Orviglance phase 3 study, SPARKLE, Last Patient Last Visit (LPLV) has been completed PDF Report Presentation Webcast
Regulatory 2023-02-10 | QUARTERLY REPORT Q4 2022: Orviglance phase 3 study, SPARKLE, expected to be completed in Q1 2023. PDF Report Presentation Webcast
Regulatory 2022-11-04 | QUARTERLY REPORT Q3 2022: Successful completion of two out of three studies for regulatory submission PDF Report Presentation Webcast
Regulatory 2022-08-18 | Half-year report 2022: Strong results from Orviglance Food Effect Study PDF Report Presentation Webcast
Regulatory 2022-05-11 | Quarterly Report Q1 2022: Strong Orviglance support from healthcare professionals PDF Report Presentation Webcast
Regulatory 2022-02-10 | Quarterly Report Q4 2021: Strong data for Orviglance vs. a gadolinium contrast agent PDF Report Presentation Webcast
Regulatory 2021-11-04 | Quarterly Report Q3 2021: Oncoral – entering clinical collaboration PDF Report Presentation Webcast
Regulatory 2021-08-19 | Quarterly Report Q2 2021: Preparing Oncoral for the next level PDF Report Presentation Webcast
Regulatory 2021-05-12 | Quarterly Report Q1 2021: US office opened in preparation of launch PDF Report Presentation Webcast
Regulatory 2021-02-16 | Quarterly Report Q4 2020: Mangoral shows high diagnostic value in new study PDF Report Presentation Webcast
Regulatory 2020-11-05 | Quarterly Report Q3-2020: Raised market estimate for Mangoral and preparing for market launch PDF Report Presentation Webcast
Regulatory 2020-08-20 | Quarterly Report Q2-2020: First participant in the hepatic study PDF Report Presentation Webcast
Regulatory 2020-05-13 | Interim Financial Report Q1-2020: First patient enrolled in Phase 3 study SPARKLE PDF Report Presentation Webcast
